Loading...
Loading...
GNFT| Name | Value |
|---|---|
| Revenues | 61.1M |
| Cost of Revenue | 0.9M |
| Gross Profit | 61.1M |
| Operating Expense | 29.9M |
| Operating I/L | 31.2M |
| Other Income/Expense | -0.9M |
| Interest Income | 0.5M |
| Pretax | 30.4M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | 30.3M |
Genfit S.A. is a biopharmaceutical company specializing in drug candidates and diagnostic solutions for metabolic and liver-related diseases. Its flagship product, Elafibranor, is in Phase 3 clinical trial for primary biliary cholangitis. The company also focuses on developing NIS4 technology for nonalcoholic steatohepatitis (NASH) diagnosis, GNS561 for cholangiocarcinoma (CCA) treatment, and Nitazoxanide for acute-on-chronic liver failure. Genfit S.A. generates revenue through licensing agreements with Labcorp for NASHnext commercialization and with Genoscience Pharma for GNS561 development and commercialization.
